Meeting Highlights
Miami, March 27, 2009
Maui, January 14-17, 2009
San Francisco, October 24-29, 2008
Paris, June 11-14, 2008
Chicago, April 10, 2008
San Francisco, March 5-9, 2008
Affiliations
ASBMR 2007 News
Surprise Data From ASBMR: Keep Antiresorptive Going When Adding Teriparatide
September 28, 2007
A randomized trial testing whether osteoporosis patients on long-term antiresorptive treatment benefit more from switching to teriparatide or from adding the new drug shows conclusively that it is better to add than to switch...
Alendronate-Related Giant Osteoclasts Reported by Two Research Groups at ASBMR
September 25, 2007
Long-term alendronate triggers formation of a new type of giant osteoclast that might lead to mistaken diagnosis of Paget's disease that does not appear to have resorptive ability, and that can still transmit signals needed by osteoclasts for bone formation, perhaps even increasing the efficacy of teriparatide...
Vitamin D + Calcium Decrease Risk of Falling; Vitamin K1 Effect Not Due to Improved BMD
September 20, 2007
Researchers at the ASBRM report that vitamin D and calcium decrease the risk of falling in postmenopausal women and that the protective effect of vitamin K1 is not due to improving BMD...Kärkkäinen M, et al; Cheung AM, et al. ASBMR 2007.
Falls Increase as Shrinking Kidney Function Lowers Balance, Muscle Strength in Elderly
September 19, 2007
Creatinine clearance of less than 65 mL/min is associated with an increased risk for falls, apparently because decreasing calcitriol serum levels jeopardizes balance and muscle strength...Dukas LC, et al. ASBMR 2007.
Inhaler Might Replace PTH Self-Injection to Prevent Postmenopausal Osteoporosis
September 18, 2007
Parathyroid hormone effectively increases postmenopausal BMD but has the downside of requiring self injection, which decreases compliance. Delivery of a PTH analogue via a dry-powder inhaler might be just as good...Morley P, et al. ASBMR 2007.
Once-Yearly Zoledronate Cuts Mortality After Hip Fracture by 28%
September 17, 2007
A single yearly dose of zoledronic acid can significantly reduce the risk of second fracture and decrease mortality in older patients who have had a hip fracture...Lyles KW, et al. ASBMR 2007.